TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Background: * Worldwide, hepatocellular carcinoma (HCC) is the fifth most common malignancy with a median survival of 6-9 months. The Study of Heart and Renal Protection (SHARP) study established Sorafenib as a standard consideration in this disease and set the bar for future studies of systemic therapy. There is no standard therapy for patients whose disease has progressed despite Sorafenib therapy. * TRC105 is a chimeric, anti-angiogenic monoclonal antibody that binds CD105, a transmembrane receptor overexpressed by proliferating endothelial cells. TRC105 binds to CD105-expressing endothelial cells and mediates growth inhibition, apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC). Objectives: Primary: -To evaluate time to tumor progression (TTP) for TRC105 in HCC. Secondary: * To evaluate safety of TRC105 in HCC. * To evaluate the immunogenicity of TRC105 as measured by human antichimeric antibody (HACA) and human antimouse antibody formation. * To evaluate anti-tumor response as determined by standard and European Association for the Study of the Liver (EASL) -modified Response Evaluation Criteria in Solid Tumors (RECIST) response criteria. * To perform correlative studies assessing potential biomarkers of response to TRC105. Eligibility: * Histologically or cytologically confirmed diagnosis of HCC. * Childs-Pugh A or B (7 points) cirrhosis only is allowed. * Patients must have disease that is not amenable to potentially curative resection. * Patients must have progressed on or been intolerant of prior sorafenib therapy. * No history of bleeding varices (unless subsequent liver transplant). All patients must have had endoscopic evaluation within 6 months of starting study. * No history of bleeding varices in previous 1 year (unless subsequent liver transplant). No anti-coagulation (except low-dose aspirin). Design: * This is a single-arm phase II study of TRC105 in patients with HCC. * TRC105 will be administered as an intravenous infusion every two weeks. Patients will be re-staged every 8 weeks. * The primary endpoint of the study will be Time to Tumor Progression (TTP). The primary purpose of this study is to evaluate the ability of TRC105 as a second line treatment to improve upon the time to progression (TTP) of patients with refractory HCC.